## Colin Green

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/545623/publications.pdf

Version: 2024-02-01

|          |                | 201674       | 265206         |
|----------|----------------|--------------|----------------|
| 56       | 1,908          | 27           | 42             |
| papers   | citations      | h-index      | g-index        |
|          |                |              |                |
|          |                |              |                |
|          |                |              |                |
| 57       | 57             | 57           | 3542           |
| all docs | docs citations | times ranked | citing authors |
|          |                |              |                |

| #  | Article   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years. Multiple Sclerosis Journal, 2022, 28, 346-351.   | 3.0  | 5         |
| 2  | Effect of a physical activity and behaviour maintenance programme on functional mobility decline in older adults: the REACT (Retirement in Action) randomised controlled trial. Lancet Public Health, The, 2022, 7, e316-e326.                                  | 10.0 | 26        |
| 3  | Cost-effectiveness of a physical activity and behaviour maintenance programme on functional mobility decline in older adults: an economic evaluation of the REACT (Retirement in Action) trial. Lancet Public Health, The, 2022, 7, e327-e334.                  | 10.0 | 10        |
| 4  | Exploring the Factors that Influence Workforce Participation for People with Multiple Sclerosis: A Discrete Choice Experiment. Journal of Occupational Rehabilitation, 2021, 31, 613-626.   | 2.2  | 4         |
| 5  | Resource Use and Cost of Subcutaneous Nerve Stimulation Versus Optimized Medical Management in Patients With Failed Back Surgery Syndrome: An Analysis of the SubQStim Study. Neuromodulation, 2021, 24, 1033-1041.   | 0.8  | O         |
| 6  | What drives differences in preferences for health states between patients and the public? A qualitative investigation of respondents' thought processes. Social Science and Medicine, 2021, 282, 114150.  | 3.8  | 5         |
| 7  | What Difference Does It Make? A Comparison of Health State Preferences Elicited From the General Population and From People With Multiple Sclerosis. Value in Health, 2020, 23, 242-250.  | 0.3  | 9         |
| 8  | Understanding and improving the experience of care for people with dementia in hospital: Developing the dementia care pointers for service change. Alzheimer's and Dementia, 2020, 16, e037772.   | 0.8  | O         |
| 9  | Informal care time in dementia by cognitive, functional and behavioral disease severity from eight longitudinal cohorts across multiple countries. Alzheimer's and Dementia, 2020, 16, e040594.   | 0.8  | O         |
| 10 | The experiences of hospital staff who provide care for people living with dementia: A systematic review and synthesis of qualitative studies. International Journal of Older People Nursing, 2020, 15, e12325.  | 1.3  | 25        |
| 11 | Activity interventions to improve the experience of care in hospital for people living with dementia: a systematic review. BMC Geriatrics, 2020, 20, 131.   | 2.7  | 7         |
| 12 | Randomised controlled trial of tailored support to increase physical activity and reduce smoking in smokers not immediately ready to quit: protocol for the Trial of physical Activity-assisted Reduction of Smoking (TARS) Study. BMJ Open, 2020, 10, e043331. | 1.9  | 6         |
| 13 | Understanding and improving experiences of care in hospital for people living with dementia, their carers and staff: three systematic reviews. Health Services and Delivery Research, 2020, 8, 1-248.   | 1.4  | 1         |
| 14 | Assessing costâ€effectiveness of early intervention in Alzheimer's disease: An openâ€source modeling framework. Alzheimer's and Dementia, 2019, 15, 1309-1321.  | 0.8  | 38        |
| 15 | Health state utility values (QALY weights) for Huntington's disease: an analysis of data from the European Huntington's Disease Network (EHDN). European Journal of Health Economics, 2019, 20, 1335-1347.  | 2.8  | 10        |
| 16 | The effects and costs of home-based rehabilitation for heart failure with reduced ejection fraction: The REACH-HF multicentre randomized controlled trial. European Journal of Preventive Cardiology, 2019, 26, 262-272.  | 1.8  | 96        |
| 17 | A Randomized Controlled Trial of Subcutaneous Nerve Stimulation for Back Pain Due to Failed Back Surgery Syndrome: The SubQStim Study. Neuromodulation, 2019, 22, 519-528.  | 0.8  | 31        |
| 18 | A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT. Health Technology Assessment, 2019, 23, 1-166.  | 2.8  | 13        |

| #  | Article  | IF           | Citations |
|----|--|--------------|-----------|
| 19 | Individual health trainers to support health and well-being for people under community supervision in the criminal justice system: the STRENGTHEN pilot RCT. Public Health Research, 2019, 7, 1-136.   | 1.3          | 6         |
| 20 | Effectiveness of the Healthy Lifestyles Programme (HeLP) to prevent obesity in UK primary-school children: a cluster randomised controlled trial. The Lancet Child and Adolescent Health, 2018, 2, 35-45.  | 5 <b>.</b> 6 | 64        |
| 21 | Where are we at with model-based economic evaluations of interventions for dementia? a systematic review and quality assessment. International Psychogeriatrics, 2018, 30, 1593-1605.  | 1.0          | 17        |
| 22 | Health State Values Derived from People with Multiple Sclerosis for a Condition-Specific Preference-Based Measure: Multiple Sclerosis Impact Scale–Eight Dimensions–Patient Version (MSIS-8D-P). Value in Health, 2018, 21, 1338-1345.                   | 0.3          | 7         |
| 23 | Health trainer-led motivational intervention plus usual care for people under community supervision compared with usual care alone: a study protocol for a parallel-group pilot randomised controlled trial (STRENGTHEN). BMJ Open, 2018, 8, e023123.    | 1.9          | 5         |
| 24 | A community-based physical activity intervention to prevent mobility-related disability for retired older people (REtirement in ACTion (REACT)): study protocol for a randomised controlled trial. Trials, 2018, 19, 228.                                | 1.6          | 26        |
| 25 | A randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with preserved ejection fraction and their caregivers: the REACH-HFpEF Pilot Study. BMJ Open, 2018, 8, e019649.                     | 1.9          | 66        |
| 26 | F26â€Quality-adjusted life-years (QALYS) and huntington's disease. , 2018, , .   |              | 0         |
| 27 | Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 312-321.   | 0.8          | 34        |
| 28 | "Naming and Framing― The Impact of Labeling on Health State Values for Multiple Sclerosis. Medical Decision Making, 2017, 37, 703-714.   | 2.4          | 5         |
| 29 | Trial baseline characteristics of a cluster randomised controlled trial of a school-located obesity prevention programme; the Healthy Lifestyles Programme (HeLP) trial. BMC Public Health, 2017, 17, 291.   | 2.9          | 5         |
| 30 | Predicting the progression of Alzheimer's disease dementia: AÂmultidomain health policy model. Alzheimer's and Dementia, 2016, 12, 776-785.  | 0.8          | 35        |
| 31 | Health Utilities for Multiple Sclerosis. Value in Health, 2016, 19, 460-468.   | 0.3          | 30        |
| 32 | Telephone triage systems in UK general practice: analysis of consultation duration during the index day in a pragmatic randomised controlled trial. British Journal of General Practice, 2016, 66, e214-e218.  | 1.4          | 36        |
| 33 | UK PATIENT PREFERENCE FOR CHARACTERISTICS OF DMTS IN MS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.23-e1.  | 1.9          | O         |
| 34 | An Exploratory Analysis of the Smoking and Physical Activity Outcomes From a Pilot Randomized Controlled Trial of an Exercise Assisted Reduction to Stop Smoking Intervention in Disadvantaged Groups. Nicotine and Tobacco Research, 2016, 18, 289-297. | 2.6          | 20        |
| 35 | A Systematic Review of the Literature on the Development of Condition-Specific Preference-Based<br>Measures of Health. Applied Health Economics and Health Policy, 2016, 14, 161-183.  | 2.1          | 36        |
| 36 | Clinical effectiveness and cost-effectiveness of collaborative care for depression in UK primary care (CADET): a cluster randomised controlled trial. Health Technology Assessment, 2016, 20, 1-192.   | 2.8          | 41        |

| #  | Article   | IF                 | CITATIONS                       |
|----|---|--------------------|---------------------------------|
| 37 | Combining behavioural activation with physical activity promotion for adults with depression: findings of a parallel-group pilot randomised controlled trial (BAcPAc). Trials, 2015, 16, 367.   | 1.6                | 30                              |
| 38 | A Quality-Adjusted Life-Year Measure for Multiple Sclerosis: Developing a Patient-Reported Health State Classification System for a Multiple Sclerosis-Specific Preference-Based Measure. Value in Health, 2015, 18, 1016-1024.   | 0.3                | 23                              |
| 39 | Estimating a Preference-Based Index for an Eight-Dimensional Health State Classification System for Multiple Sclerosis. Value in Health, 2015, 18, 1025-1036.   | 0.3                | 29                              |
| 40 | Waste the waist: a pilot randomised controlled trial of a primary care based intervention to support lifestyle change in people with high cardiovascular risk. International Journal of Behavioral Nutrition and Physical Activity, 2015, 12, 1.  | 4.6                | 307                             |
| 41 | A Systematic Review of Generic Multidimensional Patient-Reported Outcome Measures for Children, Part I: Descriptive Characteristics. Value in Health, 2015, 18, 315-333.  | 0.3                | 56                              |
| 42 | A Systematic Review of Generic Multidimensional Patient-Reported Outcome Measures for Children, Part II: Evaluation of Psychometric Performance of English-Language Versions in a General Population. Value in Health, 2015, 18, 334-345.   | 0.3                | 37                              |
| 43 | Patient perspectives on telephone triage in general practice – Authors' reply. Lancet, The, 2015, 385, 688.   | 13.7               | 5                               |
| 44 | Implementing telephone triage in general practice: a process evaluation of a cluster randomised controlled trial. BMC Family Practice, 2015, 16, 47.  | 2.9                | 20                              |
| 45 | Meaningful health outcomes for paediatric neurodisability: Stakeholder prioritisation and appropriateness of patient reported outcome measures. Health and Quality of Life Outcomes, 2015, 13, 87.  | 2.4                | 53                              |
| 46 | The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technology Assessment, 2015, 19, 1-188.  | 2.8                | 53                              |
| 47 | The clinical effectiveness and cost-effectiveness of telephone triage for managing same-day consultation requests in general practice: a cluster randomised controlled trial comparing general practitioner-led and nurse-led management systems with usual care (the ESTEEM trial). Health Technology Assessment, 2015, 19, 1-212. | 2.8                | 50                              |
| 48 | Telephone triage for management of same-day consultation requests in general practice (the ESTEEM) Tj ETQq0 1859-1868.  | 0 0 rgBT /<br>13.7 | Overlock 10 <sup>-</sup><br>156 |
| 49 | Cost-Effectiveness of Collaborative Care for Depression in UK Primary Care: Economic Evaluation of a Randomised Controlled Trial (CADET). PLoS ONE, 2014, 9, e104225.   | 2.5                | 38                              |
| 50 | Informing the NHS Outcomes Framework: evaluating meaningful health outcomes for children with neurodisability using multiple methods including systematic review, qualitative research, Delphi survey and consensus meeting. Health Services and Delivery Research, 2014, 2, 1-224.   | 1.4                | 40                              |
| 51 | A pilot randomised trial to assess the methods and procedures for evaluating the clinical effectiveness and cost-effectiveness of Exercise Assisted Reduction then Stop (EARS) among disadvantaged smokers. Health Technology Assessment, 2014, 18, 1-324.  | 2.8                | 36                              |
| 52 | A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1092-1099.   | 1.9                | 102                             |
| 53 | Using the Multiple Sclerosis Impact Scale to Estimate Health State Utility Values: Mapping from the MSIS-29, Version 2, to the EQ-5D and the SF-6D. Value in Health, 2012, 15, 1084-1091.   | 0.3                | 26                              |
| 54 | Model-Based Economic Evaluation in Alzheimer's Disease: A Review of the Methods Available to Model Alzheimer's Disease Progression. Value in Health, 2011, 14, 621-630.   | 0.3                | 56                              |

## COLIN GREEN

| #  | Article   | IF  | CITATION |
|----|---|-----|----------|
| 55 | Investigating public preferences on †severity of health' as a relevant condition for setting healthcare priorities. Social Science and Medicine, 2009, 68, 2247-2255. | 3.8 | 33       |
| 56 | Modelling Disease Progression in??Alzheimer???s Disease. Pharmacoeconomics, 2007, 25, 735-750.  | 3.3 | 39       |